Abstract
Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.
Original language | English (US) |
---|---|
Pages (from-to) | 27-35 |
Number of pages | 9 |
Journal | Pharmaceuticals Policy and Law |
Volume | 14 |
Issue number | 1 |
DOIs | |
State | Published - Feb 20 2012 |
Keywords
- Comparative effectiveness research (CER)
- effectiveness
- health technology assessment
- outcomes
- pharmacoeconomics
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Health Policy